Vasoinhibitory effect of NP-252, a new dihydropyridine derivative, in canine cerebral artery

Add time:07/27/2019    Source:sciencedirect.com

The vasoinhibitory effect of NP-252, a 1,4-dihydropyridine derivative Ca++ antagonist, was examined in canine cerebral artery, and this effect was compared with that of nifedipine. NP-252 (10−7 M) and nifedipine (10−6 M) nearly abolished the contraction induced by addition of Ca++ to Ca++-free medium containing KCl. NP-252 (10−6 M) and nifedipine (10−6 M) attenuated the contraction produced by thromboxane A2 agonist (STA2) in normal medium, and the resultant contractions were 22% (n = 6) and 35% (n = 6) of the control contraction, respectively. The vasoinhibitory effects of NP-252 were significantly stronger than those of nifedipine in canine cerebral artery. NP-252 (10−7 and 10−6 M) dose-dependently attenuated nifedipine-resistant Ca++-contraction in the presence of STA2 in both canine cerebral and coronary arteries. The inhibitory effect of combined treatment with NP-252 (10−6 M) and nitroglycerin (10−6 M) on nifedipine-resistant Ca++-contraction in the cerebral artery was additive. These results indicate that NP-252 possesses a stronger vasoinhibitory effect than that of nifedipine in canine cerebral artery.

We also recommend Trading Suppliers and Manufacturers of NP 252 (cas 132031-81-3). Pls Click Website Link as below: cas 132031-81-3 suppliers

Prev:Protein kinase C and platelet inhibition by D-erythro-sphingosine: Comparison with N,N-dimethylsphingosine and commercial preparation
Next:Yellow-emitting carbon dots for selective detecting 4-NP in aqueous media and living biological imaging)